Regeneron Reports Phase 3 Results for Dupixent in Chronic Hand Eczema

Regeneron and Sanofi today announced Phase 3 trial results for Dupixent (dupilumab) in adults with moderate-to-severe chronic hand eczema. The trial met its primary endpoint, demonstrating a significantly higher rate of clear or almost clear hands with minimal symptoms compared to placebo at week 16. These results led to FDA approval of Dupixent for chronic hand eczema.